Trifluridine/tipiracil + bevacizumab

DRUG2 trials

Sponsors

Institut de Recherches Internationales Servier, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Colorectal Cancer MetastaticColorectal Cancer RecurrentMetastatic Colorectal Cancer

Phase 2

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

CompletedNCT02743221

Institut de Recherches Internationales ServierMetastatic Colorectal Cancer

Start: 2016-04-29End: 2020-09-01Updated: 2024-08-20

Phase 3

Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer

RecruitingNCT06992648

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityColorectal Cancer Metastatic, Colorectal Cancer Recurrent

Start: 2025-04-01End: 2027-12-31Target: 302Updated: 2025-05-28

Related Papers

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

British Journal of Cancer2022-04-1916 citations

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

Journal of Clinical Oncology2021-01-207 citations

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.

2020-06-0145 citations

QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy—Results from the TASCO1 phase II study.

Journal of Clinical Oncology2019-01-292 citations